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Quinoxaline derivatives show very interesting biological properties such as antibac-
terial (1), antiviral (2), antifungal (3), anthelmintic (4) and insecticidal (5). They were
proven to be efficient anticancer agents when tested against several cell lines. Several
quinoxaline derivatives were reported to be potent and highly selective epidermal
growth factor receptor tyrosine kinase inhibitors (7). On the other hand, thioureido
sulfonamide derivatives were reported to show significant anticancer activity by acting
as carbonic anhydrase inhibitors (8). In the light of these facts and as a continuation of
our previous work (9–12), we planned to synthesize novel thioureido sulfaquinoxaline
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Sulfonamides and quinoxaline derivatives possess many
types of biological activities and have been recently re-
ported to show substantial antitumor activity. This paper
reports the synthesis of novel thioureido sulfaquinoxali-
ne derivatives. All the newly synthesized compounds were
evaluated for their in vitro anticancer activity against a
human liver cell line (HEPG2) and showed higher activ-
ity than the reference drug doxorubicin. 4-(3-(4-Ethylben-
zoate)thioureido)-N-(quinoxalin-2-yl)benzenesulfonami-
de (9) (IC50 = 15.6 mmol L–1), N-(pyridin-2-yl)-4-(3-(4-(N-
-quinoxalin-2-yl-sulfamoyl)phenyl)thioureido)benzene-
sulfonamide (10) (IC50 = 26.8 mmol L–1) and N-(quinoxa-
lin-2-yl)-4-(3-(4-(N-thiazol-2-ylsulfamoyl)phenyl)thiourei-
do)benzenesulfonamide (11) (IC50 = 24.4 mmol L–1) were
the most potent compared to doxorubicin (IC50 = 71.8
mmol L–1). The most potent compounds 9, 10 and 11 were
evaluated as radiosensitizing agents by subjecting the
compounds to g-irradiation (8 kGy).
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derivatives hoping that the new compounds might show significant anticancer activity
and to study their structure-activity relationships. Moreover, this research was also
aimed to evaluate the new compounds for their in vitro anticancer activity in combination
with g-irradiation.
EXPERIMENTAL
Melting points are uncorrected and were determined on a Stuart melting point ap-
paratus (Stuart Scientific, UK). Elemental analyses (C, H, N) were performed on a Per-
kin-Elmer 2400 analyzer (Perkin-Elmer, USA) at the Microanalytical Laboratories of the
Faculty of Science, Cairo University. All compounds were within ±0.4 % of theoretical
values. The IR spectra (KBr) were measured on a Shimadzu IR 110 Spectrophotometer
(Shimadzu, Japan), 1H NMR and 13C NMR spectra were obtained with a Bruker proton
NMR-Avance 300 instrument (300 MHz) (Bruker, Germany), in DMSO-d6 as a solvent,
using tetramethylsilane (TMS) as internal standard. Mass spectra were run using an HP
Model MS-5988 (Hewlett Packard, USA). All reactions were monitored with a thin layer
chromatography using precoated aluminum sheets (Silica gel Merck 60 F254) and were
visualized with a UV lamp (Merck, Germany). All chemicals (sulfaquinoxaline and do-
xorubicin) were commercially supplied from Sigma-Aldrich (USA).
Syntheses
4-Isothiocyanato-N-quinoxaline-2-yl-benzenesulfonamide (2). – To a suspension of sulfa-
quinoxaline 1 (3 g, 0.01 mol) in water (30 mL), thiophosgene (1 mL, 0.01 mol) was added
and the reaction mixture was stirred for 1 h until red color of the thiophosgene disap-
peared and a white precipitate was formed. The precipitate was filtered off and washed
with water to give compound 2.
4-(3-Pyridin-2-yl-thioureido)-N-(quinoxalin-2-yl)benzenesulfonamide (3). – A mixture of
2 (0.342 g, 0.01 mol) and 2-aminopyridine (0.094 g, 0.01 mol) in dimethylformamide
(DMF) (20 mL) containing 3 drops of triethylamine (TEA), was refluxed for 5 h. The solid
obtained was precipitated while hot and filtered to give compound 3.
4-(3-(5-Chloropyridin-2-yl)thioureido)-N-(quinoxalin-2-yl)benzenesulfonamide (4). – A mix-
ture of 2 (0.342 g, 0.01 mol) and 2-amino-5-chloropyridine (0.128 g, 0.001 mol) in DMF (20
mL), containing 3 drops of TEA, was refluxed for 5 h. The solid obtained was precipi-
tated while hot and filtered to give compound 4.
4-(3-(5-Bromopyridin-2-yl)thioureido)-N-(quinoxalin-2-yl)benzenesulfonamide (5). – A
mixture of 2 (0.342 g, 0.001 mol) and 2-amino-5-bromopyridine (0.173 g, 0.001 mol) in
DMF (20 mL), containing 3 drops of TEA, was refluxed for 5 h. The solid obtained was
precipitated while hot and filtered to give compound 5.
4-(3-(4-Bromophenyl)thioureido)-N-(quinoxalin-2-yl)benzenesulfonamide (6). – The mix-
ture of 2 (0.342 g, 0.01 mol) and p-bromoaniline (0.171 g, 0.001 mol) in dioxane (20 mL),
with 3 drops of TEA, was refluxed for 1 h, the solid obtained was precipitated when cold
and filtered to give compound 6.
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4-(3-(4-Fluorophenyl)thioureido)-N-(quinoxalin-2-yl)benzenesulfonamide (7). – A mixture
of 2 (0.342 g, 0.01 mol) and p-fluoroaniline (0.111 g, 0.001 mol) in dioxane (20 mL), with 3
drops of TEA, was refluxed for 1 h. The solid obtained was precipitated when cold and
filtered to give compound 7.
4-(3-(4-Chlorophenyl)thioureido)-N-(quinoxalin-2-yl)benzenesulfonamide (8). – Amixture
of 2 (0.342 g, 0.001 mol) and p-chloroaniline (0.127 g, 0.001 mol) in dioxane (20 mL), with
3 drops of TEA, was refluxed for 1 h, the solid obtained was precipitated while hot and
filtered to give compound 8.
4-(3-(4-Carbethoxy)thioureido)-N-(quinoxalin-2-yl)benzenesulfonamide (9). – A mixture of
2 (0.342 g, 0.001 mol) and benzocaine (0.165 g, 0.001 mol) in dioxane (20 mL), with 3
drops of TEA, was refluxed for 5 h. The solid obtained was precipitated when hot and
filtered to give compound 9.
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a Starting material 1 is not included in the table since it is commercially available.
b Crystallization solvent was ethanol.
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de (10). – A mixture of 2 (0.342 g, 0.01 mol) and sulfapyridine (0.233 g, 0.01 mol) in DMF
(20 mL), with 3 drops of TEA, was refluxed for 5 h. The solid was precipitated when hot
and filtered to give compound 10.
N-(Quinoxalin-2-yl)-4-(3-(4-(N-thiazol-2-ylsulfamoyl)phenyl)thioureido)benzenesulfonamide
(11). – A mixture of 2 (0.342 g, 0.001 mol) and sulfathiazole (0.239 g, 0.001 mol) in DMF
(20 mL), with 3 drops of TEA, was refluxed for 5 h. The solid was precipitated when hot
and filtered to give compound 11.
In vitro anticancer screening
The human tumor cell line (HEPG2) was obtainedfrom the National Cancer Insti-
tute, Cairo, Egypt. Irradiation was performed using a Gamma cell-40 (60Co) source
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a Starting material 1 is not included in the table since it is commercially available.
[radioactivity of one gram of 60Co is 44 TBq (about 1100 Curies)]. The antitumor activity
of the newly synthesized compounds was measured by the sulfo-rhodamine-B stain
(SRB) assay as reported by Skehan et al. (13). Cells were plated in 96-multiwell plates
(104 cells per well) for 24 h before treatment with the compounds to allow attachment of
cells to the plate wall. Tested compounds were dissolved and diluted with DMSO. Dif-
ferent concentrations of the compounds under test (5, 12.5, 25 and 40 mmol L–1) were
added to the cell monolayer. Triplicate wells were prepared for each individual dose.
Monolayer cells were incubated with the compounds for 48 h at 37 oC and in an atmo-
sphere of 5 % CO2. After 48 h, cells were fixed, washed and stained for 30 min with 0.4
% (m/V) SRB dissolved in 1 % acetic acid. Unbounded dye was removed through four
washes with 1 % acetic acid, and attached stain was recovered with Tris-EDTA buffer.
Color intensity was measured in an ELISA reader (SPR-960B Sunostick Medical Technol-
ogy, UK). Negative control was added using cell lines with the solvent without the drug.
The relation between the surviving fraction and drug concentration was plotted to get
the survival curve of each tumor cell line after a specified time. The concentration re-
quired for 50 % inhibition of cell viability (IC50) was calculated and compared with the
reference drug doxorubicin and the results are given in Table III.
Radiosensitizing activity
The most potent compounds resulting from the in vitro anticancer screening (com-
pounds 9, 10 and 11) were selected in order to evaluate their in vitro anticancer activity
in combination with g-radiation. This study was conducted to evaluate the ability of the-
se compounds to enhance the cell killing effect of g-radiation. Negative control was ad-
ded using cell lines with the solvent without the drug and radiation alone. Cells were
subjected to a single dose of g-irradiation at a dose level of 8 kGy with a dose rate of 2
kGy min–1. The surviving fractions were expressed as the mean ± standard error. The re-
sults were analyzed using the 1-way ANOVA test and are given in Table IV.
RESULTS AND DISCUSSION
Chemistry
4-Isothiocyanato-N-quinoxaline-2-yl-benzene sulfonamide 2 was prepared by the
reaction of N-quinoxaline-2-yl-benzenesulfonamide with thiophosgene as reported ear-
lier (14). Compound 2 was used to prepare different sulfonamide derivatives by incor-
porating different biologically active moieties. Compound 2 reacted with 2-aminopyri-
dine to obtain the corresponding thioureido derivative 3, while its interaction with 2-
-aminopyridine, 2-amino-5-chloropyridine and 2-amino-5-bromopyridine yielded compo-
unds 4 and 5, respectively (Scheme 1).
The isothiocyanato derivative 2 was further reacted with different aniline deriva-
tives to obtain the corresponding thioureido derivatives. Thus, its interaction with 4-bro-
moaniline, 4-fluoroaniline, 4-chloroaniline and benzocaine yielded compounds 6, 7, 8,
and 9, respectively.
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Another sulfonamide molecule was incorporated into isothiocyanate 2 through its re-
action with sulphapyridine and sulphathiazole and compounds 10 and 11 were obtai-
ned, respectively (Scheme 1).
In vitro anticancer activity
Newly synthesized compounds were evaluated for their in vitro cytotoxic activity
against a human liver cancer cell line (HEPG2). Doxorubicin, one of the most effective
anticancer agents, was used as the reference drug. The relationship between the surviv-
ing fraction and drug concentration was plotted to obtain the survival curve of the liver
cancer cell line. The response parameter calculated was the IC50 value, which corre-
sponds to the concentration required for 50 % inhibition of cell viability. Table III shows
the in vitro anticancer activity of the synthesized compounds, which exhibited signifi-
cant activity compared to the reference drug. It was found that in the negative control,
the solvent had no effect on the cells as the surviving fraction was 1.00, all the tested
compounds showed lower IC50 than doxorubicin (IC50 = 71.8 mmol L–1), with compound
9 (IC50 = 15.6 mmol L–1) being the most potent in this screening. This might be due to in-
corporation of ethylbenzoate group since the corresponding halogenated compounds 6,
7 and 8 exhibited lower activity (IC50 = 31.2–39.6 mmol L–1). Incorporation of pyridine
moiety yielding moderate activity in compound 3 (IC50 = 30.0 mmol L–1) and this activity
slightly increased to 27.6 and 28 mmol L–1, respectively, in compounds 4 and 5 contain-
ing halogenated pyridine moieties. Replacement of pyridine with sulfapyridine moiety
in compound 10 yielded an increased activity (IC50 = 26.8 mmol L–1) which was also in-
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creased upon adding the sulfathiazole moiety in compound 11 (IC50 = 24.4 mmol L–1).
Finally, it was observed that the isothiocyanate derivative 2 was the least potent in this
study (IC50 = 45 mmol L–1).
Radiosensitizing evaluation
The rationale for combining chemotherapy and radiotherapy is mainly based on two
ideas, one being spatial cooperation, which is effective if chemotherapy is sufficiently
active to eradicate subclinical metastases and if the primary local tumor is effectively
treated by radiotherapy. In this regard, no interaction between radiotherapy and chemo-
therapy is required. The other idea is the enhancement of radiation effects. Cytotoxic agents
can enhance radiation effects by direct enhancement of the initial radiation damage by
incorporating drugs into DNA, inhibiting cellular repair, accumulating cells in a radio-
sensitive phase or eliminating radioresistant phase cells, eliminating hypoxic cells or inhi-
biting the accelerated repopulation of tumor cells. Consequently, the ability of the most ac-
tive compounds (9, 10 and 11) to enhance the cell killing effect of g-irradiation was studied.
From the results given in Tables III and IV, it was concluded that in the negative control,
radiation alone had a low effect on the cells, compound 9 showed in vitro cytotoxic activ-
ity with the IC50 value of 15.6 mmol L–1 when the cells were subjected to different con-
centrations of the compound alone. However, when the cells were subjected to the same
concentrations of compound 9 and irradiated with a single dose of g-radiation of 8 kGy,
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Table III. In vitro anticancer screening of synthesized compounds against the human liver cell line
(HEPG 2)
Compd. Control
Compound concentration (mmol L–1)
IC50
(mmol L–1)
5 12.5 25 40
Surviving fractiona
Dox 1.00 0.721 ± 0.020 0.546 ± 0.020 0.461 ± 0.010 0.494 ± 0.030 71.8
2 1.00 0.934 ± 0.002 0.896 ± 0.009 0.848 ± 0.028 0.422 ± 0.047 45.0
3 1.00 0.822 ± 0.058 0.646 ± 0.026 0.530 ± 0.030 0.447 ± 0.022 30.0
4 1.00 0.876 ± 0.032 0.692 ± 0.024 0.456 ± 0.023 0.377 ± 0.015 27.6
5 1.00 0.811 ± 0.085 0.657 ± 0.016 0.503 ± 0.022 0.375 ± 0.043 28.0
6 1.00 0.921 ± 0.008 0.694 ± 0.033 0.621 ± 0.032 0.478 ± 0.081 35.2
7 1.00 0.861 ± 0.017 0.745 ± 0.015 0.557 ± 0.003 0.407 ± 0.027 31.2
8 1.00 0.818 ± 0.044 0.723 ± 0.012 0.622 ± 0.014 0.553 ±0.065 39.6
9 1.00 0.371 ± 0.074 0.298 ± 0.033 0.416 ± 0.004 0.394 ± 0.021 15.6
10 1.00 0.748 ± 0.025 0.540 ± 0.003 0.433 ± 0.076 0.437 ± 0.003 26.8
11 1.00 0.588 ± 0.021 0.507 ± 0.058 0.451 ± 0.004 0.406 ± 0.016 24.4
a Mean ± SEM, n = 3.
Dox – doxorubicin
as shown in Table IV, the IC50 value was synergistically decreased to 4.8 mmol L–1. Simi-
larly, compounds 10 and 11 showed IC50 values of 26.8 and 24.4 mmol L–1, respectively,
when used alone, but their IC50 values decreased to 12.3 and 14.7 mmol L–1, respectively,
when the cells were treated with compounds 10 or 11 in combination with g-irradiation.
These results point to the conclusion that using a combination of compounds 9, 10 or 11
and ionizing radiation synergistically enhances growth inhibition of liver cancer cells
compared to the use of each agent alone.
CONCLUSIONS
The above results allow the conclusion that administration of the tested compounds
to the human liver (HEPG2) cell lines showed promising anticancer activity. The most
potent compounds being4-(3-(4-ethylbenzoate)thioureido)-N-(quinoxalin-2-yl)benzene-
sulfonamide (9) (IC50 = 15.6 mmol L–1), N-(pyridin-2-yl)-4-(3-(4-(N-quinoxalin-2-yl-sulfa-
moyl)phenyl)thioureido)benzenesulfonamide (10) (IC50 = 26.8 mmol L–1) and N-(quino-
xalin-2-yl)-4-(3-(4-(N-thiazol-2-ylsulfamoyl)phenyl)thioureido)benzenesulfonamide (11)
(IC50 = 24.4 mmol L–1). Combining these compounds, at the same concentrations, with
radiation enhances their activity. This indicates the importance of a combination therapy
for cancer patients to reduce the side effects of both drugs and radiation.
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S A @ E T A K
Sinteza, in vitro antitumorsko ispitivanje i radiosenzitiraju}e vrednovanje novih
derivata 4-[3-(supstituiranih)tioureido]-N-(kinoksalin-2-il)benzensulfonamida
MOSTAFA M. GHORAB, FATMA A. RAGAB, HELMY I. HEIBA, MARWA G. EL-GAZZAR i MOSTAFA G. EL-GAZZAR
Derivati sulfonamida i kinoksalina imaju raznoliko biolo{ko djelovanje, izme|u
ostalog i antitumorsko djelovanje. U radu je opisana sinteza novih derivata tioureido
sulfakinoksalina. Svim novim spojevima ispitano je antitumorsko djelovanje in vitro na
humanoj stani~noj liniji jetre (HEPG 2). Svi ispitani spojevi pokazuju ja~i u~inak nego re-
ferentni lijek doksorubicin. Najja~i u~inak imali su 4-(3-(4-etilbenzoat)tioureido)-N-(ki-
noksalin-2-il)benzensulfonamid (9) (IC50 = 15,6 mmol L–1), N-(piridin-2-il)-4-(3-(4-(N-ki-
noksalin-2-il-sulfamoil)fenil)tioureido)-benzensulfonamid (10) (IC50 = 26,8 mmol L–1) i
N-(kinoksalin-2-il)-4-(3-(4-(N-tiazol-2-ilsulfamoil)fenil)tioureido)benzensulfonamid (11)
(IC50 = 24,4 mmol L–1), dok je IC50 vrijednost bila 71,8 mmol L–1. Najaktivniji spojevi 9, 10
i 11 evaluirani su kao radiosenzitiraju}a sredstva nakon izlaganja spojeva g-zra~enju
(8 kGy).
Klju~ne rije~i: kinoksalin, sulfonamid, antitumorsko djelovanje, radiosenzitiraju}i u~inak
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